Year: 2023
Type: editorial
Abstract: ver the past decade, transthyretin cardiac amyloidosis (ATTR-CM) has rapidly emerged as an increasingly diagnosed cause of heart failure (HF) among older adults, predominantly those with HF with preserved ejection fraction.Although still frequently classified as a rare disease, there is mounting evidence that ATTR-CM is not as "rare" as it has been historically described.Because of the development of effective disease-modifying therapies, such as transthyretin stabilizers, early and accurate identification of ATTR-CM is essential, as these treatments can reduce HF hospitalizations, slow the decline in loss of quality of life, and extend survival.
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,700
OpenAlex ID: W4385185998